A Multicenter Prospective Clinical Trial: Conversion Therapy for RAS/BRAF Wild-Type Right-Sided Colon Cancer Patients With Initially Unresectable Liver Metastases
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: FOLFOXIRI plus Cetuximab:FOLFOXIRI plus Cetuximab;FOLFOXIRI plus Bevacizumab:FOLFOXIRI plus Bevacizumab Primary outcome(s): conversion-to-resection rate Study Design: Parallel
创建时间：
2020-10-15
